Arjun Vasant Balar

机构：NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University · ORCID：0000-0003-3949-5656

发表论文 224 篇 · 总被引 13843 次 · h-index 37

代表论文

• TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes (2024 · Annals of Oncology · 被引 95)
• Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors (2023 · Cancer Research · 被引 39)
• Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer (2024 · Clinical Cancer Research · 被引 35)
• Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study. (2024 · Journal of Clinical Oncology · 被引 32)
• TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy (2024 · Journal of Clinical Oncology · 被引 29)
• Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial (2023 · European Urology · 被引 26)